BRIDGEWAY CAPITAL MANAGEMENT, LLC - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 76 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2020. The put-call ratio across all filers is 0.27 and the average weighting 0.3%.

Quarter-by-quarter ownership
BRIDGEWAY CAPITAL MANAGEMENT, LLC ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q1 2020$83,000
-51.7%
50,200
-35.1%
0.00%0.0%
Q4 2019$172,000
-45.2%
77,300
-47.5%
0.00%
-50.0%
Q3 2019$314,000
-42.8%
147,300
-28.1%
0.00%
-42.9%
Q2 2019$549,000
-9.9%
204,900
+65.6%
0.01%
-12.5%
Q1 2019$609,000123,7000.01%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q2 2020
NameSharesValueWeighting ↓
ACUTA CAPITAL PARTNERS, LLC 1,017,524$20,961,0007.56%
Octagon Capital Advisors LP 561,398$11,565,0004.36%
COMMODORE CAPITAL LP 369,951$7,621,0003.04%
Opaleye Management Inc. 985,000$20,291,0002.98%
VR Adviser, LLC 1,240,610$25,557,0002.77%
TSP Capital Management Group, LLC 359,229$7,400,0002.61%
RTW INVESTMENTS, LP 3,908,947$80,524,0001.26%
Ghost Tree Capital, LLC 250,000$5,150,0001.21%
Tri Locum Partners LP 196,672$4,051,0001.00%
Redmile Group, LLC 3,387,788$69,788,0000.98%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders